Infosys, Accenture To Cover COVID-19 Vaccination Costs For Indian Employees
Information Technology major Infosys Ltd and consulting and outsourcing services provider Accenture Plc said on Wednesday they would cover COVID-19 vaccination costs for their employees in India, as the country expands its massive vaccination drive.
Government's vaccination campaign ramped up on Monday, with people above the age of 60, and individuals 45 or older suffering from certain medical conditions, now eligible for shots.
Vaccines administered at government health facilities will still be free, while private facilities cannot charge more than Rs 250 per dose, the government has said.
"Infosys is looking at partnering with health care providers to vaccinate employees and their immediate families as eligible," Chief Operating Officer Pravin Rao said in an emailed statement.
For Accenture, costs for employees and dependents who are eligible and choose to receive the vaccination will be covered, the company said.
So far, the federal government has procured the two COVID-19 vaccines approved in India - AstraZeneca's shot being developed by the Serum Institute, and local player Bharat Biotech's COVAXIN - at fixed prices and distributed them free of cost.
Several companies, including autos-to-technology conglomerate Mahindra Group and consumer goods giant ITC Ltd, had already started considering buying COVID-19 vaccines for their employees as early as in January.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
